PMID- 27567825
OWN - NLM
STAT- MEDLINE
DCOM- 20180126
LR  - 20180131
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
VI  - 54
IP  - 3
DP  - 2016 Oct 4
TI  - CerefolinNAC Therapy of Hyperhomocysteinemia Delays Cortical and White Matter 
      Atrophy in Alzheimer's Disease and Cerebrovascular Disease.
PG  - 1073-1084
AB  - We examined whether using a medical food therapy for hyperhomocysteinemia (HHcy) 
      in patients with Alzheimer's disease (AD) or cognitive impairment due to 
      cerebrovascular disease (CVD) with Cerefolin(R)/CerefolinNAC(R) (CFLN: 
      L-methylfolate, methylcobalamin, and N-acetyl-cysteine) slowed regional brain 
      atrophy. Thirty HHcy patients with AD and related disorders (ADRD) received CFLN 
      (HHcy+CFLN: duration [mu +/-  sigma] = 18.6+/-16.1 months); a sub-sample of this group did 
      not receive CFLN for varying periods of time (HHcy+NoCFLN: duration 
      [mu +/-  sigma] = 12.6+/-5.6 months). Thirty-seven NoHHcy patients with ADRD did not 
      receive CFLN (NoHHcy+NoCFLN: duration [mu +/-  sigma] = 13.3+/-17.7 months). No 
      participant took supplemental B vitamins. Regional brain volumes were measured at 
      baseline and end of study, and covariate-adjusted rates of hippocampal, cortical, 
      and forebrain parenchymal (includes white matter) atrophy were predicted. The 
      HHcy+CFLN group's hippocampal and cortical atrophy adjusted rates were 4.25 and 
      11.2 times slower than those of the NoHHcy+NoCFLN group (p < 0.024). The 
      HHcy+CFLN group's forebrain parenchyma atrophy rate was significantly slower only 
      for CVD; the rate of slowing was proportional to the degree of homocysteine 
      lowering (p < 0.0001). CFLN was associated with significantly slowed hippocampal 
      and cortical atrophy rates in ADRD patients with HHcy, and forebrain parenchymal 
      atrophy rates in CVD patients with HHcy. The present results should be further 
      validated.
FAU - Shankle, William R
AU  - Shankle WR
AD  - Medical Care Corporation, Newport Beach, CA, USA.
AD  - Shankle Clinic, Newport Beach, CA, USA.
AD  - Memory and Cognitive Disorders Program, Neurosciences Institute, Hoag Memorial 
      Hospital Presbyterian, Newport Beach, CA, USA.
AD  - Department of Cognitive Sciences, University of California, Irvine, Irvine, CA, 
      USA.
FAU - Hara, Junko
AU  - Hara J
AD  - Medical Care Corporation, Newport Beach, CA, USA.
AD  - Shankle Clinic, Newport Beach, CA, USA.
FAU - Barrentine, Lori W
AU  - Barrentine LW
AD  - Nestle Health Science - Pamlab, Inc., Covington, LA, USA.
FAU - Curole, Melanie V
AU  - Curole MV
AD  - Nestle Health Science - Pamlab, Inc., Covington, LA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
RN  - 0 (Tetrahydrofolates)
RN  - 12001-76-2 (Vitamin B Complex)
RN  - BR1SN1JS2W (mecobalamin)
RN  - P6YC3EG204 (Vitamin B 12)
RN  - TYK22LML8F (5-methyltetrahydrofolate)
RN  - WYQ7N0BPYC (Acetylcysteine)
SB  - IM
MH  - Acetylcysteine/*administration & dosage
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*diagnostic imaging/diet therapy
MH  - Atrophy
MH  - Cerebral Cortex/*diagnostic imaging
MH  - Cerebrovascular Disorders/*diagnostic imaging/diet therapy
MH  - Dietary Supplements
MH  - Female
MH  - Humans
MH  - Hyperhomocysteinemia/*diagnostic imaging/diet therapy
MH  - Male
MH  - Middle Aged
MH  - Tetrahydrofolates/administration & dosage
MH  - Vitamin B 12/administration & dosage/analogs & derivatives
MH  - Vitamin B Complex/*administration & dosage
MH  - White Matter/*diagnostic imaging
OTO - NOTNLM
OT  - B12
OT  - brain atrophy
OT  - circadian rhythm
OT  - cognitive impairment
OT  - dementia
OT  - folate
OT  - hippocampus
OT  - vascular
OT  - volumetrics
OT  - white matter
EDAT- 2016/08/29 06:00
MHDA- 2018/01/27 06:00
CRDT- 2016/08/29 06:00
PHST- 2016/08/29 06:00 [pubmed]
PHST- 2018/01/27 06:00 [medline]
PHST- 2016/08/29 06:00 [entrez]
AID - JAD160241 [pii]
AID - 10.3233/JAD-160241 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2016 Oct 4;54(3):1073-1084. doi: 10.3233/JAD-160241.